

Date and Time: 15 and 16 July 2014 10am-4pm

Minutes: Agreed

Standing Committee A Meeting 4:	Long-acting reversible contraception (LARC) Irritable Bowel Syndrome (IBS)
Place:	Red Room 1, Floor 24, City Tower, Manchester.
Present:	Damien Longson (Chair) (DL) Catherine Briggs (CB) John Cape (JC) Alison Eastwood (AE) Sarah Fishburn (SF) Jim Gray (JG) Nuala Lucas (NL) [day 2 only] Kath Nuttall (KN) Tilly Pillay (TP) Nick Screatton (NS) Philippa Williams (PW) Sophie Wilne (SW) LARC Topic-specific members via video conference: Alyson Elliman (AEll) Shelley Raine Mehigan (SRM) Sonja Jutte (SJ) Jan Wake (JW) IBS Topic-specific members Mark Follows (MF) Yvonne McKenzie (YM) Marion Saunders (MS) Simon Smale (SS) Peter Whorwell (PW) [non-voting expert]
Apologies:	Alun Davies (AD) Lindsay Smith (LS) Nicola Davies (ND) [LARC Topic-specific member] Elspeth Guthrie (EG) [IBS Topic-specific member]
In attendance: NICE Staff: Phil Alderson (PA) Paul Crosland (PC) Cheryl Hookway (CH) Kathryn Hopkins (KH) Susannah Moon (SM) Katie Prickett (KP) Louise Shires (LS) Robby Richey (RR) Toni Tan (TT)	Observing: NICE staff: Emma Banks Alexa Biestry Sara Buckner Chris Gibbons Rebecca Parsons Charlotte Purves Jennifer Wells

Notes – Day 1

1. DL welcomed everyone to the fourth meeting of the clinical guidelines update standing Committee. Apologies received from AD, LS, and EG for the 2 day meeting and apologies received from ND and NL for day 1 of the meeting. The LARC topic-specific members were present in the NICE London office and joined the meeting via video conference.

DL read out the code of conduct for members of public attending the meeting. Minutes of the last meeting were agreed.

Declarations of interest were discussed and it was agreed that all interests were 'declare and participate'.

2. KH gave a presentation on the comments received from the stakeholder consultation on long-acting reversible contraception (LARC). The standing Committee and topic-specific members discussed the wording of some of the recommendations, in particular, how best to communicate changes in bleeding patterns and information about discontinuation rates. It was agreed that this discussion would be captured in the linking evidence to recommendations section of the update addendum.
3. Some of the Committee members wanted to comment on the NICE Pathway and information and it was agreed that this would be done via email.
4. DL thanked the LARC topic-specific Committee members for their input in the update and asked them to feedback to the NICE team their experiences. The LARC topic-specific members and public observers left the meeting.
5. DL welcomed the irritable bowel topic-specific members to the meeting and read the code of conduct for members of public attending the meeting. Declarations of interest were discussed and it was agreed that all interests were 'declare and participate'. It was noted that PW was a non-voting expert for the IBS update.
6. PW provided a clinical overview of IBS and the Committee members had opportunity to ask the topic-specific members questions. RR recapped the review protocol for the IBS update and then presented the evidence for review question one – as low-dose tricyclic antidepressants (TCAs), SSRIs and SNRIs effective in the management of IBS (including which are more effective). The Committee agreed the evidence statements and discussed the quality of the evidence in relation to the answering of the review question.

The public were informed that the second part of the meeting was closed to the public due to the confidential nature of the business conducted.

7. The standing Committee drafted recommendations for the first review question.

Notes – Day 2

1. DL welcomed everyone to the second day of the clinical guidelines update standing Committee and read out the code of conduct for members of public attending the meeting. Declarations of interest were discussed and it was agreed that all interests were 'declare and participate'.
2. YM presented an overview of the low FODMAP diet and the Committee had opportunity to ask the topic-specific members questions. RR then recapped the review protocol for this review question.
3. RR presented the evidence for review question 2 – does a low FODMAP diet have an effect on the symptoms of IBS? The Committee discussed the evidence and agreed the evidence statements.

The public were informed that the second part of the meeting was closed to the public due to the confidential nature of the business conducted.

4. The Committee drafted recommendations for this review question.
5. PC presented an overview of health economics and discussed how economics might impact the IBS update.

Date and venue of the next meeting:

12 September 2014, Red Room 1, Floor 24, City Tower, Manchester.